Cyclodextrin-Based Approach in Biotechnology

A special issue of Future Pharmacology (ISSN 2673-9879).

Deadline for manuscript submissions: closed (30 October 2023) | Viewed by 5199

Special Issue Editors


E-Mail Website
Guest Editor
Department of Vaccine Technology, Vaccine Institute, Hacettepe University, 06100 Ankara, Turkey
Interests: bionanotechnology; cyclodextrin; adjuvant; vaccine development; nanoparticle; drug delivery; immunochemotherapy; 3D cell culture

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey
Interests: pharmaceutical technology; nanodelivery systems; pharmaceutcal cosmetology; cyclodextrin nanoparticles; anticancer drug delivery; nanocosmetics

Special Issue Information

Dear Colleagues,

Cyclodextrins have been known for over a century and are still being developed. They are cyclic oligosaccharides composed of glucopyranose subunits arranged in a truncated cone structure with a lipophilic interior cavity and a hydrophilic surface. Cyclodextrins are preferred in a wide variety of fields to improve stability, increase water solubility, reduce undesirable side effects, and mask taste and odor, thanks to their ability to form complexes with a wide variety of molecules and mask the physicochemical properties of the guest molecule. An enormous number of derivatives are synthesized through surface modification, cross-linked polymerization, or reconstruction of the skeleton of natural cyclodextrins.

Cyclodextrins have been important and widely used polymers in the field of biotechnology due to their features. They are used in each and every aspect of biotechnology, including vaccine and drug formulation development, disease diagnosis and treatment, fermentation, agriculture, the food industry, cosmetics, and tissue engineering.

This Special Issue of Future Pharmacology aims to collect the most recent uses and the latest applications of cyclodextrins in the broad spectrum of biotechnology.

Dr. Gamze Varan
Dr. Nazlı Erdoǧar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • vaccine
  • personalized medicine
  • biotechnology
  • nanoparticulate systems
  • tissue engineering
  • regenerative medicine
  • theradiagnostics
  • bioengineering

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 4864 KiB  
Article
Design of a Cyclodextrin Bioproduction Process Using Bacillus pseudofirmus and Paenibacillus macerans
by Alexandre Miguel Guedes, Tiago Filipe Santos Alves, Paulo J. Salústio, Helena M. Cabral-Marques and Maria H. L. Ribeiro
Future Pharmacol. 2023, 3(3), 568-584; https://doi.org/10.3390/futurepharmacol3030035 - 11 Jul 2023
Viewed by 2004
Abstract
Cyclodextrin (CD) drug delivery systems offer the potential to enhance the desired physicochemical properties and pharmacokinetic parameters of drugs while maintaining their safety. Cyclodextrin-glucosyl-transferase (CGTase) is amongst the most important enzymes used in CD biosynthesis. However, the bioproduction of CDs still faces challenges [...] Read more.
Cyclodextrin (CD) drug delivery systems offer the potential to enhance the desired physicochemical properties and pharmacokinetic parameters of drugs while maintaining their safety. Cyclodextrin-glucosyl-transferase (CGTase) is amongst the most important enzymes used in CD biosynthesis. However, the bioproduction of CDs still faces challenges in terms of optimization and process complexity. This study proposes a novel CD bioproduction system in a batch mode to increase yield and reduce costs. Two bacterial strains were selected: the alkalophilic Bacillus pseudofirmus DSM2517 strain and the neutrophilic Paenibacillus macerans DSM1574 strain. Three different culture media, two temperatures (30 °C and 37 °C), and three scales (shake flasks 20 mL and 100 mL, and bioreactor 3.2 L) were evaluated with respect to bacterial growth kinetics, protein production, and CGTase biosynthesis and activity for β-CD production. Bacterial growth was monitored by measuring optical density (OD600 nm), while CGTase activity was assessed by measuring β-CD production directly in the medium after filtration or in samples after concentration (using a Vivaspin 500® ultrafiltration spin column with a 10 kDa cut-off). β-CD quantification was performed using the phenolphthalein colorimetric method and HPLC. The best conditions for combined growth and protein production, for both microorganisms, in shake flasks were achieved with a medium containing 2% dextrin as the carbohydrate source. Scale-up to the bioreactor displayed improved growth kinetics for both bacteria and higher protein production and CGTase activity for Paenibacillus macerans. Full article
(This article belongs to the Special Issue Cyclodextrin-Based Approach in Biotechnology)
Show Figures

Figure 1

Review

Jump to: Research

15 pages, 520 KiB  
Review
Cyclodextrin in Vaccines: Enhancing Efficacy and Stability
by Gamze Varan
Future Pharmacol. 2023, 3(3), 597-611; https://doi.org/10.3390/futurepharmacol3030038 - 24 Aug 2023
Cited by 1 | Viewed by 2506
Abstract
Cyclodextrins, a family of cyclic oligosaccharides, have received considerable interest in the field of pharmaceuticals due to their unique molecular structure and versatile properties. In the context of vaccines, cyclodextrins can effectively encapsulate antigens, ensuring their protection from degradation and improving their immunogenicity. [...] Read more.
Cyclodextrins, a family of cyclic oligosaccharides, have received considerable interest in the field of pharmaceuticals due to their unique molecular structure and versatile properties. In the context of vaccines, cyclodextrins can effectively encapsulate antigens, ensuring their protection from degradation and improving their immunogenicity. Cyclodextrins offer stability advantages to vaccines by preventing the degradation of labile vaccine components during storage and transportation. Furthermore, cyclodextrins can serve as adjuvants, potentiating the immune response triggered by vaccines. Their unique structure and interaction with the immune system enhance the recognition of antigens by immune cells, leading to an improved activation of both innate and adaptive immune responses. This adjuvant effect contributes to the development of robust and long-lasting immune protection against targeted pathogens. Owing to the distinctive attributes inherent to nanoparticles, their integration into vaccine formulations has assumed an imperative role. Through the encapsulation of vaccine antigens/adjuvants within cyclodextrin nanoparticles, the potency and stability of vaccines can be notably enhanced. In particular, the capacity of amphiphilic cyclodextrins to form nanoparticles through self-assembly without surfactants or co-solvents is a captivating prospect for their application as carrier systems for antigens. In conclusion, cyclodextrins present a promising platform for enhancing the efficacy and stability of vaccines. Their ability to encapsulate antigens, stabilize labile vaccine components and act as adjuvants demonstrates their potential to revolutionize vaccine formulation and delivery. Further research and development in this field will facilitate the translation of cyclodextrin-based vaccine technologies into practical and impactful immunization strategies, ultimately benefiting global health and disease prevention. Full article
(This article belongs to the Special Issue Cyclodextrin-Based Approach in Biotechnology)
Show Figures

Graphical abstract

Back to TopTop